LI
FE

Health and research sectors are in a significant process of change and consolidation. On the one hand, the elimination of barriers to entry that prevented foreign companies from providing private health care services in Brazil has resulted in a new dynamic in the market. On the other, high-end equipment, new treatment options, and innovative pharmaceuticals and cosmetics require constant updating. The challenge is to navigate the Brazilian regulatory environment, which is evolving at a slower pace.

Our firm works to facilitate new business. In the health sector, we advise private groups interested in investing in Brazil by carrying out audits of assets and conducting risk assessments.

We also advise on such issues as importation of machinery, technology transfer agreements, regularization of labor issues (to minimize and isolate liabilities), and matters of a regulatory nature.

In the pharmaceutical and cosmetics industry, our role is to assist investors and companies in general in understanding existing regulatory and bureaucratic barriers in order to explore the vast potential of the market, including making good and sustainable use of Brazil’s genetic heritage (in clinical trials and research).

Our industry experience includes services in the following areas:

  • Mergers and acquisitions
  • Regulatory consulting in the context of the Ministry of Health, ANS (National Health Agency), ANVISA (National Health Surveillance Agency), and MAP (Ministry of Agriculture and Livestock)
  • Consulting with respect to access to Brazil's genetic heritage and traditional knowledge associated with benefit sharing, and interacting with the Genetic Heritage Management Council (CGEN)
  • Advice on labor issues
  • Preparation of licensing and technology transfer agreements
  • Tax consulting
  • Litigation

RELATED PARTNERS

São Paulo
São Paulo
São Paulo
São Paulo
São Paulo
São Paulo
São Paulo
Rio de Janeiro
São Paulo
São Paulo
São Paulo
São Paulo
São Paulo
São Paulo
São Paulo